FrancophonIA/ELRC3.0 huggingface dataset:
English: Talk to your doctor, pharmacist or nurse before using Herzuma if:
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primite lijek Herzuma:
English: Trastuzumab 1 Year N = 1693
Croatian: Trastuzumab tijekom 1 godine N = 1693
English: After reconstitution with sterile water for injection the reconstituted solution is physically and chemically stable for 7 days at 2ºC - 8ºC.
Croatian: Nakon rekonstitucije sa sterilnom vodom za injekcije rekonstituirana otopina je fizički i kemijski stabilna 7 dana na temperaturi 2 - 8°C.
English: For instructions on reconstitution of Herzuma intravenous formulation before administration, see section 6.6.
Croatian: Za upute o rekonstituciji lijeka Herzuma u intravenskoj formulaciji prije primjene vidjeti dio 6.6.
English: In the pivotal trial (BO16216), trastuzumab and anastrozole were administered from day 1.
Croatian: U pivotalnom kliničkom ispitivanju (BO16216) trastuzumab i anastrozol primjenjivani su od prvoga dana.
English: Herzuma is a biosimilar medicinal product.
Croatian: Herzuma je biosličan lijek.
English: Herzuma may have a minor influence on the ability to drive or use machines (see section 4.8).
Croatian: Herzuma može imati manji utjecaj na sposobnost upravljanja vozilima i rada sa strojevima (vidjeti dio 4.8).
English: Chemo + trastuzumab (n=115)
Croatian: Kemoterapija + trastuzumab (n = 115)
English: No incompatibilities between Herzuma and polyvinylchloride, polyethylene or polypropylene bags have been observed.
Croatian: Nisu primijećene inkompatibilnosti između lijeka Herzuma i polivinilkloridnih, polietilenskih ili polipropilenskih vrećica.
English: There is no relevant use of Herzuma in the paediatric population.
Croatian: Nema relevantne primjene lijeka Herzuma u pedijatrijskoj populaciji.
English: Other side effects can occur at any time during treatment with Herzuma, not just related to an infusion.
Croatian: Ostale nuspojave mogu se pojaviti bilo kada tijekom liječenja lijekom Herzuma, a ne samo u svezi s infuzijom.
English: For early breast cancer, metastatic breast cancer and metastatic gastric cancer, Herzuma is given every 3 weeks.
Croatian: Za rani rak dojke, metastatski rak dojke i metastatski rak želuca, Herzuma se primjenjuje svaka 3 tjedna.
English: Clinically significant interactions between Herzuma and the concomitant medicinal products used in clinical trials have not been observed.
Croatian: Nisu primijećene klinički značajne interakcije između lijeka Herzuma i istodobno primijenjenih lijekova koji su se koristili u kliničkim ispitivanjima.
English: Treatment with Herzuma alone or with a taxane may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine used to treat cancer).
Croatian: Liječenje lijekom Herzuma samim ili u kombinaciji s taksanom može utjecati na srce, osobito ako ste nekada već uzimali antracikline (taksani i antraciklini su dvije vrste lijekova koji se koriste za liječenje raka).
English: FP + H: Fluoropyrimidine/cisplatin + trastuzumab FP: Fluoropyrimidine/cisplatin a: Odds ratio
Croatian: FP + H: fluoropirimidin/cisplatin + trastuzumab FP: fluoropirimidin/cisplatin : omjer šansi
English: Millmount Healthcare Ltd. Block 7
Croatian: Millmount Healthcare Ltd.
English:  you have early breast cancer, with high levels of a protein called HER2.
Croatian: • bolujete od ranog raka dojke s visokom razinom proteina koji se zove HER2.
English: Herzuma is for single-use only, as the product contains no preservatives.
Croatian: Herzuma je namijenjen samo za jednokratnu primjenu jer ne sadrži konzervanse.
English: Your doctor may prescribe Herzuma for the treatment of breast and gastric cancer when:
Croatian: Vaš liječnik Vam može propisati lijek Herzuma za liječenje raka dojke i želuca ako:
English: During a Herzuma infusion, chills, fever and other flu like symptoms may occur.
Croatian: Za vrijeme infuzije lijeka Herzuma mogu se pojaviti zimica, vrućica i drugi simptomi nalik gripi.
English: The efficacy results from the BO16348 trial following 12 months* and 8 years** median follow-up are summarised in Table 6:
Croatian: Rezultati djelotvornosti dobiveni ispitivanjem BO16348, nakon medijana praćenja od 12 mjeseci* i 8 godina**, sažeti su u Tablici 6:
English: If a pregnant woman is treated with Herzuma, or if a patient becomes pregnant while receiving Herzuma or within 7 months following the last dose of Herzuma, close monitoring by a multidisciplinary team is desirable.
Croatian: Ako se lijekom Herzuma liječi trudnicu, ili ako bolesnica zatrudni tijekom liječenja lijekom Herzuma ili unutar 7 mjeseci nakon posljednje doze lijeka Herzuma, poželjno je pažljivo praćenje od strane multidisciplinarnog tima.
English: 1 Year N = 1702***
Croatian: Trastuzumab tijekom 1 godine N = 1702***
English: The exploratory analyses of covariates with information in only a subset of patients suggested that patients with greater shed HER2-ECD level had faster nonlinear clearance (lower Km) (p < 0.001).
Croatian: Eksploracijske analize kovarijanti na temelju podataka prikupljenih samo u jednoj podskupini bolesnika pokazali su da su bolesnici s višom razinom odcjepljivanja HER2-ECD-a imali brži nelinearni klirens (niži Km) (p < 0,001).
English: In patients who receive anthracycline-containing chemotherapy further monitoring is recommended, and should occur yearly up to 5 years from the last administration of Herzuma, or longer if a continuous decrease of LVEF is observed.
Croatian: U bolesnika koji primaju kemoterapiju koja sadrži antracikline, preporučuje se daljnje praćenje jednom godišnje do 5 godina od posljednje primjene lijeka Herzuma ili dulje ako je uočeno daljnje smanjenje LVEF-a.
English: *Cmin,ss = Cmin at steady state **Cmax,ss = Cmax at steady state *** time to 90% of steady state
Croatian: *Cmin,ss - Cmin u stanju dinamičke ravnoteže **Cmax,ss = Cmax u stanju dinamičke ravnoteže ***vrijeme do postizanja 90% stanja dinamičke ravnoteže
English: The safety of continuation or resumption of Herzuma in patients who experience cardiac dysfunction has not been prospectively studied.
Croatian: Sigurnost kontinuirane ili ponovne primjene lijeka Herzuma u bolesnika u kojih se razvila disfunkcija srca nije prospektivno ispitana.
English: No formal medicinal product interaction studies have been performed.
Croatian: Nisu provedena formalna ispitivanja interakcija s drugim lijekovima.
English:  you have severe breathing problems at rest due to your cancer or if you need oxygen treatment.
Croatian: • ako zbog raka imate ozbiljnih poteškoća s disanjem u mirovanju ili Vam je potrebno liječenje kisikom.
English:  you have had heart failure, coronary artery disease, heart valve disease (heart murmurs), high blood pressure, taken any high blood pressure medicine or are currently taking any high blood pressure medicine.
Croatian: • Ako ste imali zatajenje srca, bolest srčanih arterija, bolest srčanih zalistaka (šum na srcu), visok krvni tlak, ako ste uzimali lijekove za liječenje visokog krvnog tlaka ili trenutno uzimate lijekove za liječenje visokog krvnog tlaka.
English: Table 6 Efficacy results from study BO16348
Croatian: Tablica 6 Rezultati djelotvornosti iz ispitivanja BO16348
English: A careful risk-benefit assessment should be made before deciding to treat with Herzuma.
Croatian: Potrebna je pomna procjena rizika i koristi liječenja prije donošenja odluke o liječenju lijekom Herzuma.
English: As human IgG1 is secreted into human milk, and the potential for harm to the infant is unknown, women should not breast-feed during Herzuma therapy and for 7 months after the last dose.
Croatian: Budući da se humani IgG1 izlučuje u majčino mlijeko u ljudi, a nema spoznaja o mogućem štetnom učinku na novorođenče, žene ne bi smjele dojiti tijekom liječenja lijekom Herzuma ni 7 mjeseci nakon posljednje doze lijeka.
English:  you have ever had or are currently using a medicine called doxorubicin or epirubicin (medicines used to treat cancer).
Croatian: • Ako ste ikada primali ili trenutno primate lijek koji se zove doksorubicin ili epirubicin (lijekovi za liječenje raka).
English: If you stop using Herzuma
Croatian: Ako prestanete primati lijek Herzuma
English: The presence of anti-trastuzumab antibodies had no impact on pharmacokinetics, efficacy (determined by pathological Complete Response [pCR] and event free survival [EFS]) and safety determined by occurrence of administration related reactions (ARRs) of trastuzumab intravenous.
Croatian: Prisutnost protutijela na trastuzumab nije utjecala na farmakokinetiku, djelotvornost (određenu potpunim patološkim odgovorom [engl. pathological complete response, pCR] i preživljenjem bez događaja [engl. event-free survival, EFS]) niti sigurnost određenu na temelju nastupa reakcija povezanih s primjenom lijeka trastuzumabom za intravensku primjenu.
English: Women of childbearing potential should be advised to use effective contraception during treatment with Herzuma and for 7 months after treatment has concluded (see section 5.2).
Croatian: Ženama reproduktivne dobi potrebno je preporučiti učinkovitu kontracepciju tijekom terapije lijekom Herzuma i 7 mjeseci nakon prestanka liječenja (vidjeti dio 5.2).
English: On the basis of the scientific conclusions for trastuzumab the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing trastuzumab is unchanged subject to the proposed changes to the product information
Croatian: Na temelju znanstvenih zaključaka za trastuzumab, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) trastuzumab nepromijenjen, uz predložene izmjene informacija o lijeku.
English: t1/2 range from Cmax,ss to Cmin,ss (day)
Croatian: Raspon t1/2 do Cmax,ss do Cmin,ss
English:  Hypersensitivity to trastuzumab, murine proteins, or to any of the excipients listed in section 6.1.
Croatian: • Preosjetljivost na trastuzumab, mišje proteine ili neku od pomoćnih tvari navedenih u dijelu 6.1.
English: A vial of Herzuma reconstituted with water for injections (not supplied) is stable for 7 days at 2ºC - 8ºC after reconstitution and must not be frozen.
Croatian: Sadržaj bočice lijeka Herzuma rekonstituiran s vodom za injekcije (nije priložena u pakiranju) stabilan je 7 dana na temperaturi od 2°C - 8°C nakon rekonstitucije i ne smije se zamrzavati.
English: Do not breast-feed your baby during Herzuma therapy and for 7 months after the last dose of Herzuma as Herzuma may pass to your baby through your breast milk.
Croatian: Nemojte dojiti dijete za vrijeme terapije lijekom Herzuma ni 7 mjeseci nakon posljednje doze lijeka jer se Herzuma preko vašeg mlijeka može prenijeti na vaše dijete.
English: Placental transfer of trastuzumab during the early (days 20 - 50 of gestation) and late (days 120 - 150 of gestation) foetal development period was observed.
Croatian: Primijećeno je da trastuzumab prolazi kroz posteljicu za vrijeme ranog (20. - 50. dan gestacije) i kasnog (120. - 150. dan gestacije) perioda fetalnog razvoja.
English: AC→PH (vs. AC→P) (NSABP B-31 and NCCTG N9831)*
Croatian: AC→PH (naspram AC→P) (NSABP B-31 i NCCTG N9831)
English: If you experience any of the above symptoms when your treatment with Herzuma has finished, you should see your doctor and tell them that you have previously been treated with Herzuma.
Croatian: Ako se neki od gore navedenih simptoma jave nakon prestanka liječenja lijekom Herzuma, javite se svojem liječniku i recite mu da ste prethodno bili liječeni lijekom Herzuma.
English: Therefore, from the mechanism of action there is evidence that trastuzumab can cause tumour lysis syndrome.
Croatian: Stoga iz njegova mehanizma djelovanja proizlazi da trastuzumab može uzrokovati sindrom tumorske lize.
English: Do not use Herzuma if you notice any particulate matter or discoloration prior to administration.
Croatian: Herzuma se ne smije upotrijebiti ako primijetite bilo kakve čestice ili promjenu boje prije primjene.
English: For overall survival, the HR was 0.75 (95% CI 0.51 - 1.11) in the IHC 2+/FISH+ group and the HR was 0.58 (95% CI 0.41 - 0.81) in the IHC 3+/FISH+ group.
Croatian: HR za ukupno preživljenje je bio 0,75 (95% CI 0,51 - 1,11) u skupini IHC 2+/FISH+ i 0,58 (95% CI 0,41 - 0,81) u skupini IHC 3+/FISH+.
English:  CMF on day 1 and 8 every 4 weeks for 3 cycles which was followed after surgery by
Croatian: • CMF 1. i 8. dana svaka 4 tjedna u 3 ciklusa a zatim nakon kirurškog zahvata
English: Observation N=1693
Croatian: Opservacija N = 1693
English: Although the number of cases identified by a search of the safety database and meeting the CairoBishop criteria for diagnosis was low, it is endorsed that a contributing factor of trastuzumab to tumour lysis syndrome (TLS) could not be excluded.
Croatian: Premda je broj slučajeva koji su utvrđeni pretraživanjem baze sigurnosnih podataka i koji su zadovoljavali Cairo-Bishopove dijagnostičke kriterije bio malen, smatra se da se trastuzumab ne može isključiti kao faktor koji pridonosi sindromu tumorske lize.
English: At the time of a safety update after a median of 3.5 - 3.8 years follow up, an analysis of DFS reconfirms the magnitude of the benefit shown in the definitive analysis of DFS.
Croatian: U vrijeme kontrole sigurnosti primjene nakon medijana praćenja od 3,5 - 3,8 godina, analiza preživljenja bez bolesti ponovno je potvrdila značajnu korist prikazanu u konačnoj analizi preživljenja bez bolesti.
English: What you need to know before you use Herzuma
Croatian: Što morate znati prije nego počnete primati lijek Herzuma
English: If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping Herzuma.
Croatian: Ako je moguće, uputno je izbjegavati primjenu antraciklinske terapije do 7 mjeseci nakon prestanka primjene lijeka Herzuma.
English: If diluted aseptically, it may be stored for 24 hours (do not store above 30ºC).
Croatian: Ako je otopina za infuziju pripravljana u aseptičkim uvjetima, može se čuvati 24 sata (ne čuvati na temperaturi iznad 30°C).
English: Combination treatment with trastuzumab and anastrozole
Croatian: Kombinirano liječenje trastuzumabom i anastrozolom
English: Post-hoc exploratory analysis with DFS and symptomatic cardiac events Long term follow-up hazard ratios (95% CI)
Croatian: Post-hoc eksplorativna analiza s preživljenjem bez bolesti i simptomatskim srčanim događajima Dugoročno praćenje Omjeri hazarda (95% CI)
English: Patients treated with Herzuma are at increased risk for developing CHF (New York Heart Association [NYHA] Class II - IV) or asymptomatic cardiac dysfunction.
Croatian: U bolesnika liječenih lijekom Herzuma postoji povećan rizik od razvoja kongestivnog zatajenja srca (engl. congestive heart failure, CHF) (klase II - IV prema New York Heart Association [NYHA]) ili asimptomatske disfunkcije srca.
English: Risk factors for a cardiac event identified in four large adjuvant studies included advanced age (> 50 years), low LVEF (< 55%) at baseline, prior to or following the initiation of paclitaxel treatment, decline in LVEF by 10 - 15 points, and prior or concurrent use of anti-hypertensive medicinal products.
Croatian: Faktori rizika za srčani događaj utvrđeni u četiri velika ispitivanja adjuvantnog liječenja uključivali su stariju dob (> 50 godina), nizak LVEF (< 55%) na početku liječenja, prije ili nakon početka liječenja paklitakselom, pad LVEF-a za 10 - 15 bodova te prethodnu ili istodobnu primjenu antihipertenziva.
English: Herzuma treatment should only be initiated by a physician experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a healthcare professional only.
Croatian: Liječenje lijekom Herzuma smije započeti samo liječnik s iskustvom u primjeni citotoksične kemoterapije (vidjeti dio 4.4), a lijek smije primijeniti samo zdravstveni radnik.
English: An absolute benefit of 13 percentage points in favour of the trastuzumab arm was estimated in terms of 3-year event-free survival rate (65% versus 52%).
Croatian: Za skupinu koja je primala trastuzumab procijenjena je apsolutna korist od 13 postotnih bodova za stopu trogodišnjeg preživljenja bez štetnih događaja (65% naspram 52%).
English: Herzuma contains the active substance trastuzumab, which is a monoclonal antibody.
Croatian: Lijek Herzuma sadrži djelatnu tvar trastuzumab, koji je monoklonsko protutijelo.
English: In 3 pivotal clinical trials of adjuvant trastuzumab given in combination with chemotherapy, the incidence of grade 3/4 cardiac dysfunction (specifically symptomatic Congestive Heart Failure) was similar in patients who were administered chemotherapy alone (i.e. did not receive trastuzumab) and in patients who were administered trastuzumab sequentially after a taxane (0.3 - 0.4%).
Croatian: U 3 pivotalna klinička ispitivanja adjuvantne primjene trastuzumaba u kombinaciji s kemoterapijom, incidencija disfunkcije srca stupnja 3/4 (osobito simptomatsko kongestivno zatajenje srca) je bila slična u bolesnika koji su primili samo kemoterapiju (dakle, nisu primili trastuzumab) i u bolesnika koji su primili trastuzumab nakon taksana (0,3 - 0,4%).
English: A volume overage of 4% ensures that the labelled dose of 420 mg can be withdrawn from each vial.
Croatian: Višak volumena od 4% jamči da se naznačena doza od 420 mg može izvući iz svake bočice.
English: More patients experienced at least one grade 3 or 4 adverse event in the 2-year treatment arm (20.4%) compared with the 1-year treatment arm (16.3%).
Croatian: Barem jedan štetan događaj stupnja 3 ili 4 pojavio se u više bolesnika u skupini liječenoj tijekom 2 godine (20,4%) u usporedbi sa skupinom liječenom tijekom 1 godine (16,3%).
English: In a method comparison study (study D008548), a high degree of concordance (> 95%) was observed for SISH and FISH techniques for the detection of HER2 gene amplification in gastric cancer patients.
Croatian: U ispitivanju uspoređivanja metoda (ispitivanje D008548) u bolesnika s rakom želuca ustanovljen je visok stupanj podudarnosti (> 95%) za SISH i FISH metode utvrđivanja genske amplifikacije HER2.
English: In Study BO16348, after a median follow-up of 8 years the incidence of severe CHF (NYHA Class III & IV) in the trastuzumab 1 year treatment arm was 0.8%, and the rate of mild symptomatic and asymptomatic left ventricular dysfunction was 4.6%.
Croatian: U ispitivanju BO16348, nakon medijana praćenja od 8 godina, incidencija teškog kongestivnog zatajenja srca (NYHA klase III i IV) u skupini liječenoj 1 godinu trastuzumabom iznosila je 0,8%, dok je stopa blage simptomatske i asimptomatske disfunkcije lijeve klijetke iznosila 4,6%.
English: In BCIRG 006 study, 213/1075 patients in the DCarbH (TCH) arm, 221/1074 patients in the AC→DH (AC→TH) arm, and 217/1073 in the AC→D (AC→T) arm had a Karnofsky performance status ≤ 90 (either 80 or 90).
Croatian: U ispitivanju BCIRG 006 je 213/1075 bolesnica u skupini DCarbH (TCH), 221/1074 bolesnica u skupini AC→DH (AC→TH) i 217/1073 bolesnica u skupini AC→D (AC→T) imalo Karnofsky status ≤ 90 (bilo 80 ili 90).
English: Currently no data from clinical trials are available on re-treatment of patients with previous exposure to Herzuma in the adjuvant setting.
Croatian: Trenutno nema dostupnih podataka dobivenih kliničkim ispitivanjima o ponovnom liječenju bolesnika koji su prethodno adjuvantno liječeni lijekom Herzuma.
English: If you receive Herzuma with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin you should also read the patient information leaflets for these products.
Croatian: Ako primate lijek Herzuma u kombinaciji s nekim drugim lijekom za liječenje raka, poput paklitaksela, docetaksela, inhibitora aromataze, kapecitabina, 5-fluorouracila ili cisplatina, pročitajte uputu o lijeku i za te lijekove.
English: Biotec Services International Ltd. Biotec House
Croatian: Biotec Services International Ltd.
English:  If you have any further questions, ask your doctor or pharmacist.
Croatian: • Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
English: In order to prevent medication errors it is important to check the vial labels to ensure that the medicine being prepared and given is Herzuma (trastuzumab) and not trastuzumab emtansine.
Croatian: U svrhu sprečavanja medikacijskih pogrešaka, važno je provjeriti naljepnice na bočicama kako biste bili sigurni da je lijek koji se priprema i primjenjuje Herzuma (trastuzumab), a ne trastuzumab emtanzin.
English: Studies of HER2-positivity rates in gastric cancer (GC) using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) or chromogenic in situ hybridisation (CISH) have shown that there is a broad variation of HER2-positivity ranging from 6.8% to 34.0% for IHC and 7.1% to 42.6% for FISH.
Croatian: Ispitivanja stupnja ekspresije HER2 u bolesnika s rakom želuca uporabom imunohistokemije (IHC) i fluorescentne in situ hibridizacije (FISH) ili kromogene in situ hibridizacije (CISH) pokazala su veliku varijabilnost ekspresije HER2 u rasponu od 6,8% do 34,0% kod IHC-a i od 7,1% do 42,6% kod FISH-a.
English: In patients receiving trastuzumab after completion of adjuvant chemotherapy, the risk of cardiac dysfunction was associated with a higher cumulative dose of anthracycline given prior to initiation of trastuzumab and a body mass index (BMI) > 25 kg/m
Croatian: U bolesnika koji su trastuzumab primali nakon završetka adjuvantne kemoterapije, rizik od disfunkcije srca povezivao se s većom kumulativnom dozom antraciklina primijenjenoga prije početka liječenja trastuzumabom te indeksom tjelesne mase (BMI) većim od 25 kg/m
English: Patients with history of myocardial infarction (MI), angina pectoris requiring medical treatment, history of or existing CHF (NYHA Class II - IV), LVEF of < 55%, other cardiomyopathy, cardiac arrhythmia requiring medical treatment, clinically significant cardiac valvular disease, poorly controlled hypertension (hypertension controlled by standard medical treatment eligible), and hemodynamic effective pericardial effusion were excluded from adjuvant and neoadjuvant EBC pivotal trials with trastuzumab and therefore treatment cannot be recommended in such patients.
Croatian: Bolesnici koji su imali infarkt miokarda (IM) u anamnezi, anginu pektoris koju treba liječiti, ranije ili postojeće kongestivno zatajenje srca (NYHA klase II - IV), LVEF < 55%, neku drugu kardiomiopatiju, srčanu aritmiju koju treba liječiti, klinički značajnu bolest srčanih zalistaka, loše kontroliranu hipertenziju (hipertenzija kontrolirana standardnim liječenjem nije predstavljala prepreku) i hemodinamički učinkovit perikardijalni izljev bili su isključeni iz pivotalnih ispitivanja adjuvantnog i neoadjuvantnog liječenja ranog raka dojke trastuzumabom, pa se liječenje za te bolesnike ne može preporučiti.
English: Table 12 Efficacy results from MO16432
Croatian: Tablica 12 Rezultati djelotvornosti iz ispitivanja MO16432
English: • increased muscle tone or tension (hypertonia)
Croatian: • povećani tonus ili napetost mišića
English:  you have metastatic gastric cancer with high levels of HER2, when it is in combination with the other cancer medicines capecitabine or 5-fluorouracil and cisplatin.
Croatian: • bolujete od metastatskog raka želuca s visokom razinom proteina HER2, u kombinaciji s drugim lijekovima za liječenje raka, kapecitabinom ili 5-fluorouracilom i cisplatinom.
English: If symptomatic cardiac failure develops during Herzuma therapy, it should be treated with standard medicinal products for CHF.
Croatian: Ako se tijekom liječenja lijekom Herzuma razvije simptomatsko zatajenje srca, potrebno je primijeniti standardne lijekove koji se propisuju za CHF.
English: Herzuma intravenous infusion should be administered by a health-care provider prepared to manage anaphylaxis and an emergency kit should be available.
Croatian: Intravensku infuziju lijeka Herzuma treba dati stručni zdravstveni radnik obučen za liječenje anafilaksije, a na raspolaganju treba biti oprema za hitne slučajeve.
English: - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.
Croatian: - nakon adjuvantne kemoterapije doksorubicinom i ciklofosfamidom u kombinaciji s paklitakselom ili docetakselom